Aripiprazole
Product Images NDC 17856-0680

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Aripiprazole (NDC 17856-0680). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Atlantic Biologicals Corps, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 3 (Aripiprazole 3figure)

This chart depicts fold changes with 90% confidence intervals for pharmacokinetic parameters (AUC and Cmax) relative to reference values without interacting drugs. The drugs listed on the vertical axis include CYP2D6 substrates (dextromethorphan), CYP2C9 and CYP2C19 substrates (warfarin and its enantiomers), UGT1A4 substrate (lamotrigine), and other compounds such as valproate, lithium, lorazepam, venlafaxine and its metabolite, and escitalopram. The horizontal axis shows the magnitude of change relative to reference from 0.5 to 3.*

FDA Label Image

Figure 2 (Aripiprazole Figure2)

A pharmacokinetic chart titled 'Effect of Other Drugs on Aripiprazole' showing fold change and 90% confidence intervals for AUC and Cmax of dehydro-aripiprazole relative to reference without interacting drug. It compares the effects of CYP3A4 inhibitors (ketoconazole), CYP2D6 inhibitors (quinidine), CYP3A4 inducers (carbamazepine), gastric acid blockers (famotidine), and other drugs (valproate, lithium, lorazepam) on aripiprazole's pharmacokinetics.*

FDA Label Image

Figure 4 (Aripiprazole Figure4)

A pharmacokinetic chart titled 'Aripiprazole Fold Change and 90% CI' depicting the relative change in AUC and Cmax across special populations including CYP2D6 metabolizer status, gender, age groups, hepatic impairment levels, and severe renal impairment compared to reference groups. The horizontal axis shows change relative to reference on a scale from 0.5 to 3.0.*

FDA Label Image

Figure 5 (Aripiprazole Figure5)

A pharmacokinetic chart showing fold change and 90% confidence intervals for Dehydro-Aripiprazole comparing various factors relative to a reference. Factors include CYP2D6 metabolism status, gender, age groups, hepatic impairment levels, and severe renal impairment. Axes represent fold change relative to reference for AUC and Cmax values.*

FDA Label Image

Figure 6 (Aripiprazole Figure6)

A Kaplan-Meier survival curve graph showing the proportion of subjects with relapse over 182 days from randomization. Two groups are compared: one treated with Aripiprazole (solid line) and a placebo group (dashed line). The graph includes a table below indicating the number of subjects at risk at various time points for both groups.*

FDA Label Image

Figure 7 (Aripiprazole Figure7)

A line graph comparing the proportion of subjects with relapse over days from randomization between Aripiprazole and placebo groups. The graph includes subject risk counts at multiple time points for both groups, with Aripiprazole represented by a solid line and placebo by a dashed line.*

FDA Label Image

Structure (Aripiprazole Str)

Chemical structure of the active ingredient Aripiprazole, showing a complex molecule with two chlorine-substituted rings connected via nitrogen atoms to an oxygen-containing heterocyclic structure.*

FDA Label Image

Trigen Laboratories Llc (Aripiprazole Trigen)

FDA Label Image

Label Image (Lbl178560680)

Aripiprazole 5 mg tablets packaging label from Atlantic Biologicals Corps. The label includes NDC 17856-0680-01 and contains information on tablet use, storage instructions, and safety warnings to keep the medication out of reach of children. It also provides contact details for questions and a barcode for scanning.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.